DK176464B1 - Rekombinant poxvirus og vaccine mod herpesvirus indeholdende dette - Google Patents
Rekombinant poxvirus og vaccine mod herpesvirus indeholdende dette Download PDFInfo
- Publication number
- DK176464B1 DK176464B1 DK199101743A DK174391A DK176464B1 DK 176464 B1 DK176464 B1 DK 176464B1 DK 199101743 A DK199101743 A DK 199101743A DK 174391 A DK174391 A DK 174391A DK 176464 B1 DK176464 B1 DK 176464B1
- Authority
- DK
- Denmark
- Prior art keywords
- recombinant
- virus
- gene
- ehv
- plasmid
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 137
- 241001529453 unidentified herpesvirus Species 0.000 title claims description 97
- 229960005486 vaccine Drugs 0.000 title claims description 65
- 241000700618 Vaccinia virus Species 0.000 claims description 245
- 108090000623 proteins and genes Proteins 0.000 claims description 208
- 108090000288 Glycoproteins Proteins 0.000 claims description 155
- 102000003886 Glycoproteins Human genes 0.000 claims description 151
- 101700012268 Holin Proteins 0.000 claims description 83
- 101710124413 Portal protein Proteins 0.000 claims description 81
- 101710112672 Probable tape measure protein Proteins 0.000 claims description 80
- 101710194975 Uncharacterized protein gp14 Proteins 0.000 claims description 80
- 150000001413 amino acids Chemical class 0.000 claims description 75
- 238000003780 insertion Methods 0.000 claims description 63
- 230000037431 insertion Effects 0.000 claims description 63
- 101710099276 Probable metalloendopeptidase Proteins 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 238000000338 in vitro Methods 0.000 claims description 23
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims description 22
- 230000036039 immunity Effects 0.000 claims description 21
- PZOHPVWRSNXCRP-QRCCJXOFSA-N GPL-1 Chemical compound C([C@@H](NC(=O)CC(O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCC)C(=O)N[C@H]([C@@H](C)OC1[C@@H]([C@H](O)[C@H](O)[C@H](C)O1)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)C(=O)N[C@H](C)C(=O)N[C@@H](C)COC1[C@@H]([C@H](OC)[C@@H](OC)[C@H](C)O1)O)C1=CC=CC=C1 PZOHPVWRSNXCRP-QRCCJXOFSA-N 0.000 claims description 20
- 238000012217 deletion Methods 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 238000002255 vaccination Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 16
- 230000008774 maternal effect Effects 0.000 claims description 14
- 241000700663 Avipoxvirus Species 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 244000144977 poultry Species 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 6
- 241000178270 Canarypox virus Species 0.000 claims description 5
- 108010062697 pseudorabies virus glycoproteins Proteins 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 description 283
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 258
- 239000012634 fragment Substances 0.000 description 234
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 192
- 210000004027 cell Anatomy 0.000 description 144
- 206010046865 Vaccinia virus infection Diseases 0.000 description 142
- 208000007089 vaccinia Diseases 0.000 description 142
- 108020004414 DNA Proteins 0.000 description 87
- 239000002773 nucleotide Substances 0.000 description 54
- 125000003729 nucleotide group Chemical group 0.000 description 53
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 47
- 101710177717 Terminase small subunit Proteins 0.000 description 45
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 44
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 44
- 108091028043 Nucleic acid sequence Proteins 0.000 description 44
- 230000000890 antigenic effect Effects 0.000 description 42
- 108700026244 Open Reading Frames Proteins 0.000 description 40
- 239000000047 product Substances 0.000 description 40
- 108091034117 Oligonucleotide Proteins 0.000 description 38
- 239000013598 vector Substances 0.000 description 36
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 32
- 239000011543 agarose gel Substances 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 31
- 230000006798 recombination Effects 0.000 description 31
- 108091081024 Start codon Proteins 0.000 description 30
- 108091026890 Coding region Proteins 0.000 description 29
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 28
- 238000005215 recombination Methods 0.000 description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 27
- 238000010166 immunofluorescence Methods 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 25
- 241000700584 Simplexvirus Species 0.000 description 24
- 230000015556 catabolic process Effects 0.000 description 24
- 238000006731 degradation reaction Methods 0.000 description 24
- 101150029683 gB gene Proteins 0.000 description 24
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 23
- 241000282887 Suidae Species 0.000 description 23
- 230000003472 neutralizing effect Effects 0.000 description 23
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 22
- 101150061732 M2L gene Proteins 0.000 description 22
- 108020004705 Codon Proteins 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 21
- 108010012716 Felid herpesvirus 1 glycoprotein B Proteins 0.000 description 21
- 230000036961 partial effect Effects 0.000 description 21
- 101710194278 Late genes activator p4 Proteins 0.000 description 20
- 101710188472 Probable portal protein Proteins 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 241000699800 Cricetinae Species 0.000 description 19
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 19
- 239000012528 membrane Substances 0.000 description 19
- 210000003501 vero cell Anatomy 0.000 description 19
- 230000002209 hydrophobic effect Effects 0.000 description 18
- 230000003053 immunization Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 18
- 230000001681 protective effect Effects 0.000 description 18
- 238000010276 construction Methods 0.000 description 17
- 238000001114 immunoprecipitation Methods 0.000 description 17
- 241000700198 Cavia Species 0.000 description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 108010005774 beta-Galactosidase Proteins 0.000 description 15
- 210000000170 cell membrane Anatomy 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 108020005038 Terminator Codon Proteins 0.000 description 13
- 101150036031 gD gene Proteins 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 13
- 101710154606 Hemagglutinin Proteins 0.000 description 12
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 12
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 12
- 101710176177 Protein A56 Proteins 0.000 description 12
- 238000012300 Sequence Analysis Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 101150002378 gC gene Proteins 0.000 description 12
- 239000000185 hemagglutinin Substances 0.000 description 12
- 231100000518 lethal Toxicity 0.000 description 12
- 230000001665 lethal effect Effects 0.000 description 12
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 230000002238 attenuated effect Effects 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 10
- 108010017826 DNA Polymerase I Proteins 0.000 description 10
- 102000004594 DNA Polymerase I Human genes 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 101150055782 gH gene Proteins 0.000 description 10
- 239000002054 inoculum Substances 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 101150039660 HA gene Proteins 0.000 description 9
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 9
- 108020004440 Thymidine kinase Proteins 0.000 description 9
- 238000004873 anchoring Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- 108010069621 Epstein-Barr virus EBV-associated membrane antigen Proteins 0.000 description 8
- 230000004988 N-glycosylation Effects 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 241000287219 Serinus canaria Species 0.000 description 7
- 102000006601 Thymidine Kinase Human genes 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 6
- 101900120730 Equine herpesvirus 1 Envelope glycoprotein E Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 102000005936 beta-Galactosidase Human genes 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 5
- 101150068622 ATI gene Proteins 0.000 description 5
- 241000714165 Feline leukemia virus Species 0.000 description 5
- 101000805977 Human cytomegalovirus (strain Towne) Unique short US11 glycoprotein Proteins 0.000 description 5
- 208000032420 Latent Infection Diseases 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 108700026226 TATA Box Proteins 0.000 description 5
- 101150003725 TK gene Proteins 0.000 description 5
- 206010000210 abortion Diseases 0.000 description 5
- 231100000176 abortion Toxicity 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 101150030521 gI gene Proteins 0.000 description 5
- 101150040331 gM gene Proteins 0.000 description 5
- 101150106093 gpt gene Proteins 0.000 description 5
- 238000002169 hydrotherapy Methods 0.000 description 5
- 229940031551 inactivated vaccine Drugs 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 101150033839 4 gene Proteins 0.000 description 3
- 101710112753 A-type inclusion protein A25 homolog Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710189078 Helicase Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 101710159453 Proximal tail tube connector protein Proteins 0.000 description 3
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 3
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 101710199973 Tail tube protein Proteins 0.000 description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 101150118312 gp63 gene Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000007505 plaque formation Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 208000009305 pseudorabies Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 101710104895 DNA replication protein 17 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
- 206010053317 Hydrophobia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108020005350 Initiator Codon Proteins 0.000 description 2
- 102100024407 Jouberin Human genes 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100243739 Mus musculus Pgpep1 gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710152616 Probable major capsid protein gp17 Proteins 0.000 description 2
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 101100451967 Rattus norvegicus Ephx1 gene Proteins 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 108010059485 brain synaptic membrane glycoprotein gp 50 Proteins 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 101150015940 gL gene Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- MIAKOEWBCMPCQR-YBXAARCKSA-N (2s,3r,4s,5r,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=CC(N)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MIAKOEWBCMPCQR-YBXAARCKSA-N 0.000 description 1
- 101150078635 18 gene Proteins 0.000 description 1
- IWTBVKIGCDZRPL-LURJTMIESA-N 3-Methylbutanol Natural products CC[C@H](C)CCO IWTBVKIGCDZRPL-LURJTMIESA-N 0.000 description 1
- 101710183434 ATPase Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 1
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 1
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 1
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 1
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 1
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 1
- 101100121429 Arabidopsis thaliana GCL2 gene Proteins 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 1
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 1
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 1
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 1
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 1
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 1
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 1
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101150044735 C7L gene Proteins 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710086913 DNA polymerase Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 235000019005 Digitaria californica Nutrition 0.000 description 1
- 241001115843 Digitaria californica Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000725578 Equid gammaherpesvirus 2 Species 0.000 description 1
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 1
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 1
- 102100023303 Germ cell-less protein-like 1 Human genes 0.000 description 1
- 101710170453 Glycoprotein 55 Proteins 0.000 description 1
- 101710138378 Glycoprotein GX Proteins 0.000 description 1
- 101150101366 HSV2 gene Proteins 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 1
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 1
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 1
- 101000830085 Homo sapiens Germ cell-less protein-like 1 Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 1
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 1
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 1
- 241000701043 Lymphocryptovirus Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 1
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 1
- 101100281686 Mus musculus Fstl1 gene Proteins 0.000 description 1
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100447536 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pgi-1 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710195254 Non-structural glycoprotein Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 1
- 101710137389 Probable tail terminator protein Proteins 0.000 description 1
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 1
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 1
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 1
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 1
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 1
- 241000272171 Scolopacidae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 1
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 1
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 1
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 1
- 101001039145 Suid herpesvirus 1 (strain Rice) Envelope glycoprotein I Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 1
- 101100002024 Thermus aquaticus pstI gene Proteins 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010073328 Undifferentiated nasopharyngeal carcinoma Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 101100382201 Vaccinia virus (strain Copenhagen) C7L gene Proteins 0.000 description 1
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 1
- 241000700646 Vaccinia virus WR Species 0.000 description 1
- 101900123149 Varicella-zoster virus Envelope glycoprotein E Proteins 0.000 description 1
- 101900123177 Varicella-zoster virus Envelope glycoprotein I Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 1
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 101150072564 gE gene Proteins 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000024934 humoral immune response mediated by circulating immunoglobulin Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK200701150A DK200701150A (da) | 1989-04-17 | 2007-08-13 | Rekombinant poxvirus og vaccine mod herpesvirus indeholdende dette |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33900489A | 1989-04-17 | 1989-04-17 | |
US33900489 | 1989-04-17 | ||
US39448889A | 1989-08-16 | 1989-08-16 | |
US39448889 | 1989-08-16 | ||
US50283490 | 1990-04-04 | ||
US07/502,834 US5338683A (en) | 1981-12-24 | 1990-04-04 | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US9002094 | 1990-04-16 | ||
PCT/US1990/002094 WO1990012882A1 (en) | 1989-04-17 | 1990-04-16 | Herpes virus recombinant poxvirus vaccine |
Publications (3)
Publication Number | Publication Date |
---|---|
DK174391D0 DK174391D0 (da) | 1991-10-15 |
DK174391A DK174391A (da) | 1991-12-12 |
DK176464B1 true DK176464B1 (da) | 2008-03-31 |
Family
ID=27407304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK199101743A DK176464B1 (da) | 1989-04-17 | 1991-10-15 | Rekombinant poxvirus og vaccine mod herpesvirus indeholdende dette |
Country Status (17)
Country | Link |
---|---|
US (3) | US5338683A (it) |
JP (2) | JP3083839B2 (it) |
KR (1) | KR920700289A (it) |
AT (1) | AT405184B (it) |
AU (1) | AU625623B2 (it) |
BE (1) | BE1004369A5 (it) |
CA (1) | CA2014465C (it) |
CH (1) | CH682671A5 (it) |
DE (2) | DE4090565C2 (it) |
DK (1) | DK176464B1 (it) |
FR (1) | FR2647808B1 (it) |
GB (1) | GB2246784B (it) |
IE (1) | IE61098B1 (it) |
IT (1) | IT1241119B (it) |
LU (1) | LU88018A1 (it) |
NL (1) | NL195016C (it) |
WO (1) | WO1990012882A1 (it) |
Families Citing this family (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
GB9014950D0 (en) * | 1990-07-06 | 1990-08-29 | Univ Glasgow | Ehv-4 glycoprotein vaccine |
US5674735A (en) * | 1990-07-06 | 1997-10-07 | University Court Of The University Of Glasgow | DNA encoding the EHV-4 gH or gC glycoprotein |
WO1992005263A1 (en) * | 1990-09-25 | 1992-04-02 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
US7374768B1 (en) * | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5759552A (en) * | 1991-03-07 | 1998-06-02 | Virogenetics Corporation | Marek's disease virus recombinant poxvirus vaccine |
GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
EP0538496B1 (en) * | 1991-08-26 | 2003-10-29 | Baxter Healthcare S.A. | Recombinant fowlpox virus with intact FPV-tk-gene |
EP0561034B1 (en) | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Direct molecular cloning of a modified chordopox virus genome |
US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
AU696247B2 (en) * | 1993-02-26 | 1998-09-03 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
US6010703A (en) * | 1993-07-26 | 2000-01-04 | Board Of Trustees Operating Michigan State University | Recombinant poxvirus vaccine against feline rhinotracheitis |
WO1995026751A1 (en) * | 1994-03-30 | 1995-10-12 | Virogenetics Corporation | NUCLEOTIDE AND AMINO ACID SEQUENCES OF CANINE HERPESVIRUS gB, gC and gD AND USES THEREFOR |
WO1995030018A2 (en) * | 1994-04-29 | 1995-11-09 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
AU737243B2 (en) | 1996-07-03 | 2001-08-16 | Merial, Inc. | Recombinant canine adenovirus (CAV) containing exogenous DNA |
US6183752B1 (en) * | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
ES2315008T5 (es) | 1998-02-24 | 2012-03-06 | Sisters Of Providence In Oregon | Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral. |
BR9908267A (pt) | 1998-02-27 | 2000-10-24 | Univ Pennsylvania | Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo |
AU3498200A (en) | 1999-02-19 | 2000-09-04 | Michigan State University | An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid |
BR0008645A (pt) | 1999-03-03 | 2002-01-22 | Univ Pennsylvania | Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição |
WO2000066162A1 (en) | 1999-04-30 | 2000-11-09 | The Trustees Of The University Of Pennsylvania | Mutant human cd80 and compositions for and methods of making and using the same |
CA2375320C (en) * | 1999-06-10 | 2013-02-19 | Merial | Dna vaccines for pets or for animals used in sports |
WO2000076538A1 (en) | 1999-06-10 | 2000-12-21 | Michigan State University | Feline calicivirus isolated from cat urine and vaccines thereof |
CA2382026A1 (en) | 1999-09-02 | 2001-03-08 | Ruth A. Vrable | Vaccine to control equine protozoal myeloencephalitis in horses |
US7419668B1 (en) | 1999-09-02 | 2008-09-02 | Board Of Trustees Of Michigan State University | Vaccine to control equine protozoal myeloencephalitis in horses |
DE60038048T2 (de) * | 1999-12-21 | 2009-07-09 | Merial | Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe |
CN1312171C (zh) * | 2000-07-14 | 2007-04-25 | 宾夕法尼亚州立大学托管会 | 可编码hiv辅助蛋白的dna疫苗 |
AU2002211490A1 (en) * | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
NZ524661A (en) * | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US20020108132A1 (en) * | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
US7541512B2 (en) * | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
EP1478751A4 (en) * | 2001-03-30 | 2005-10-19 | Avigenics Inc | LYSOZYM PROMOTER IN BIRDS |
US7176300B2 (en) * | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
US20040037848A1 (en) * | 2001-04-06 | 2004-02-26 | Audonnet Jean-Christophe Francis | Recombinant vaccine against West Nile Virus |
FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
US7740863B2 (en) * | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
AU2002329176A1 (en) | 2001-05-25 | 2002-12-23 | The Trustees Of The University Of Pennsylvania | Targeted particles and methods of using the same |
US7550650B2 (en) * | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
US7294507B2 (en) * | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
US20100333219A1 (en) * | 2001-11-30 | 2010-12-30 | Synageva Biopharma Corp. | Methods of protein production using ovomucoid regulatory regions |
US7335761B2 (en) * | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
US7135562B2 (en) * | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
US20040241723A1 (en) * | 2002-03-18 | 2004-12-02 | Marquess Foley Leigh Shaw | Systems and methods for improving protein and milk production of dairy herds |
EP1839672A3 (en) * | 2002-04-19 | 2007-11-21 | Bavarian Nordic A/S | Modified vaccinia virus Ankara for the vaccination of neonates |
EA007811B1 (ru) | 2002-05-16 | 2007-02-27 | Бавариан Нордик А/С | Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva) |
KR101044538B1 (ko) * | 2002-09-05 | 2011-06-27 | 버베리안 노딕 에이/에스 | 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법 |
AU2003296974A1 (en) * | 2002-12-13 | 2004-07-14 | Aventis Pasteur, Inc. | Production of alvac on avian embryonic stem cells |
CN1980571A (zh) * | 2003-01-24 | 2007-06-13 | 阿维季尼克斯股份有限公司 | 禽类及禽蛋中表达的外源蛋白质 |
US7262027B2 (en) * | 2003-03-14 | 2007-08-28 | Medical College Of Ohio | Polypeptide and DNA immunization against Coccidioides spp. infections |
EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
ATE535249T1 (de) | 2003-06-13 | 2011-12-15 | Univ Pennsylvania | Vakzine, immuntherapeutika und verfahren zu ihrer verwendung |
NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
WO2005049794A2 (en) | 2003-11-13 | 2005-06-02 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
ATE510928T1 (de) | 2004-02-19 | 2011-06-15 | Univ Alberta | Leptinpromotor-polymorphismen und verwendungen davon |
WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
WO2006056487A2 (en) | 2004-11-24 | 2006-06-01 | Theraptosis S.A. | Peptides useful as dual caspase-2/-6 inhibitors and their biological applications |
US20080064862A1 (en) * | 2004-12-29 | 2008-03-13 | Avigenics, Inc. | Transgene expression in a avians |
ES2343270T3 (es) | 2005-04-25 | 2010-07-27 | Merial Ltd. | Vacunas contra el virus nipah. |
ATE496629T1 (de) * | 2005-07-28 | 2011-02-15 | Pfizer Prod Inc | Impfstoff gegen felines calicivirus (fcv), der ein fcv kapsid protein oder ein isoliertes fcv kapsid protein mit der protein sequenz seq id no: 13 oder mit einer protein sequenz, die zumindestens zu 95 identisch zur seq id no: 13 ist enthält. |
US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
EP3147296A1 (en) | 2005-11-14 | 2017-03-29 | Merial, Inc. | Gene therapy for renal failure |
US7745158B2 (en) * | 2005-12-14 | 2010-06-29 | Kimberly-Clark Worldwide, Inc. | Detection of secreted aspartyl proteases from Candida species |
ATE533782T1 (de) * | 2006-01-13 | 2011-12-15 | Univ Pennsylvania | Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür |
EP1981905B1 (en) | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Chlamydia vaccine |
EP2019687B1 (en) | 2006-03-29 | 2014-03-19 | Merial Limited | Vaccine against streptococci |
US20090060947A1 (en) * | 2006-05-19 | 2009-03-05 | Sanofi Pasteur, Inc. | Immunological compositions |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
CA3057039C (en) | 2006-07-28 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Hiv consensus envelope sequences and methods for using same |
US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
KR101445903B1 (ko) | 2007-05-02 | 2014-09-29 | 메리얼 리미티드 | 향상된 발현 및 안정성을 갖는 dna 플라스미드 |
TW200907058A (en) | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
US20090246226A1 (en) * | 2008-03-28 | 2009-10-01 | Zeon Corporation | Avian vaccines possessing a positive marker gene |
WO2009124309A2 (en) | 2008-04-04 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same |
KR101589511B1 (ko) * | 2008-04-04 | 2016-02-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 치쿤구니야 바이러스 단백질의 공통 서열, 이를 인코딩하는 핵산 분자, 조성물 및 이를 이용하는 방법 |
ES2760004T3 (es) | 2008-05-08 | 2020-05-12 | Boehringer Ingelheim Animal Health Usa Inc | Vacuna contra Leishmania utilizando un inmunnógeno salival de mosca de la arena |
JP5753090B2 (ja) | 2008-10-29 | 2015-07-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改良型hcvワクチンおよびその使用方法 |
US8921536B2 (en) | 2008-10-29 | 2014-12-30 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
CA2653478A1 (en) * | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
US9050287B2 (en) | 2009-01-23 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
US20100192236A1 (en) * | 2009-01-28 | 2010-07-29 | University Of South Carolina | Modulation of Delta Opioid Receptor Expression |
CN102428099B (zh) | 2009-04-03 | 2016-03-16 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
US20100284977A1 (en) * | 2009-04-28 | 2010-11-11 | University Of South Carolina | Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters |
EP2424999A1 (en) | 2009-04-30 | 2012-03-07 | Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) | Modified immunization vectors |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
AU2010291900A1 (en) | 2009-09-14 | 2012-03-22 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
WO2011054011A2 (en) | 2009-11-02 | 2011-05-05 | The Trustees Of The University Of Pennsylvania | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
AU2011213559B2 (en) | 2010-02-08 | 2015-05-07 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same |
US9109007B2 (en) | 2010-08-18 | 2015-08-18 | Purdue Pharma L.P. | MHC-I restricted epitopes containing non-natural amino acid residues |
MX344103B (es) | 2010-08-31 | 2016-12-05 | Merial Ltd | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. |
AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
ES2718846T3 (es) | 2010-11-12 | 2019-07-04 | Univ Pennsylvania | Antígenos de próstata consenso, molécula de ácido nucleico que los codifica y la vacuna y usos que los comprenden |
WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
KR20140007404A (ko) | 2011-01-31 | 2014-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법 |
PL2672992T3 (pl) | 2011-02-11 | 2020-11-02 | The Trustees Of The University Of Pennsylvania | Cząsteczka kwasu nukleinowego kodująca białko rdzeniowe wirusa zapalenia wątroby typu B i szczepionka je zawierająca |
US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
EP2694678A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
CN103945864A (zh) | 2011-04-25 | 2014-07-23 | 先进生物学实验室股份有限公司 | 截短的hiv包膜蛋白(env)、其相关方法和组合物 |
US9669085B2 (en) | 2011-06-01 | 2017-06-06 | Merial Inc. | Needle-free administration of PRRSV vaccines |
US9446114B2 (en) | 2011-07-11 | 2016-09-20 | Inovio Pharmaceuticals, Inc. | Cross-protective arenavirus vaccines and their method of use |
RU2591817C2 (ru) | 2011-07-20 | 2016-07-20 | Мериал Лимитед | Рекомбинантная вакцина вируса лейкемии кошек, содержащая оптимизированный ген оболочки вируса лейкемии кошек |
CN103841963B (zh) | 2011-08-12 | 2018-04-24 | 梅里亚股份有限公司 | 用于生物产品特别是疫苗的真空辅助保存 |
AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
KR20220035279A (ko) | 2011-10-12 | 2022-03-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법 |
CA2851336C (en) | 2011-10-24 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Improved hcv vaccines and methods for using the same |
MX354986B (es) | 2011-12-12 | 2018-03-28 | Univ Pennsylvania | Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso. |
CA2858884A1 (en) | 2011-12-12 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections |
WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
BR112014023414B1 (pt) * | 2012-03-20 | 2022-08-30 | Boehringer Ingelheim Animal Health USA Inc. | Vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos |
EP3511337A1 (en) | 2012-04-10 | 2019-07-17 | The Trustees of The University of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
WO2014127825A1 (en) | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim Vetmedica Gmbh | H5 proteins of h5n1 influenza virus for use as a medicament |
EP2968514A1 (en) | 2013-03-12 | 2016-01-20 | Merial, Inc. | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
EP3586870A1 (en) | 2013-03-12 | 2020-01-01 | The Trustees Of The University Of Pennsylvania | Improved vaccines for human papilloma virus and methods for using the same |
EP3756683A1 (en) | 2013-03-15 | 2020-12-30 | The Trustees Of The University Of Pennsylvania | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
EP3607974A1 (en) | 2013-03-15 | 2020-02-12 | The Trustees of The University of Pennsylvania | Cancer vaccines and methods of treatment using the same |
AU2015241107B2 (en) | 2014-04-03 | 2019-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Porcine epidemic diarrhea virus vaccine |
NZ731659A (en) | 2014-11-03 | 2018-10-26 | Merial Inc | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
PL3313864T3 (pl) | 2015-06-23 | 2022-01-03 | Boehringer Ingelheim Animal Health USA Inc. | Rekombinowane wektory wirusowe zawierające drugorzędne białko prrsv oraz sposoby ich wytwarzania i zastosowania |
ES2778649T3 (es) | 2015-08-31 | 2020-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Vacunas pestivirales para temblores congénitos |
MX2018003173A (es) | 2015-09-16 | 2018-05-17 | Boehringer Ingelheim Vetmedica Inc | Vacunas de salmonella choleraesuis-salmonella typhimurium. |
EP3515480A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New swine influenza vaccine |
AR109540A1 (es) | 2016-09-20 | 2018-12-19 | Boehringer Ingelheim Vetmedica Gmbh | Moléculas promotoras para expresar antígenos virales |
CN109715204B (zh) | 2016-09-20 | 2023-08-22 | 勃林格殷格翰动物保健有限公司 | 新的ehv插入位点orf70 |
TW201823467A (zh) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 犬腺病毒載體 |
WO2018083154A1 (en) | 2016-11-03 | 2018-05-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus |
MY191895A (en) | 2016-11-03 | 2022-07-18 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
JP2020506915A (ja) | 2017-01-30 | 2020-03-05 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | ブタコロナウイルスワクチン |
WO2019014144A1 (en) | 2017-07-12 | 2019-01-17 | Boehringer Ingelheim Vetmedica, Inc. | IMMUNOGENIC COMPOSITIONS BASED ON SENECAVIRUS TYPE A AND CORRESPONDING METHODS |
CA3072553A1 (en) | 2017-09-23 | 2019-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Paramyxoviridae expression system |
WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
KR20230116954A (ko) | 2017-12-13 | 2023-08-04 | 이노비오 파마수티컬즈, 인크. | Muc16을 표적화하는 암 백신 및 이의 용도 |
WO2019118760A1 (en) | 2017-12-13 | 2019-06-20 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting mesothelin and uses thereof |
BR112020011443A2 (pt) | 2017-12-13 | 2020-12-01 | Inovio Pharmaceuticals, Inc. | molécula de ácido nucleico e seu uso, vetor e seu uso, composição, proteína e vacina |
RU2711907C2 (ru) * | 2017-12-22 | 2020-01-23 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | Рекомбинантный белок, содержащий антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (варианты) |
AU2019223768A1 (en) | 2018-02-23 | 2020-08-27 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom |
CA3091960A1 (en) | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | New ehv insertion site ul43 |
AR115002A1 (es) | 2018-03-19 | 2020-11-18 | Boehringer Ingelheim Vetmedica Gmbh | Ehv con ul18 y/o ul8 inactivados |
JP7162072B2 (ja) | 2018-03-26 | 2022-10-27 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 免疫原性組成物を製造する方法 |
CN112867506A (zh) | 2018-09-20 | 2021-05-28 | 勃林格殷格翰动物保健有限公司 | 抗猪流行性腹泻的鼻内载体疫苗 |
EP3852797A1 (en) | 2018-09-20 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Modified pedv spike protein |
EP4100420A1 (en) | 2020-02-06 | 2022-12-14 | Boehringer Ingelheim Vetmedica GmbH | Polypeptides useful for detecting anti-rhabdovirus antibodies |
WO2022076977A1 (en) | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Animal Health USA Inc. | Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof |
WO2022076979A1 (en) | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Fusion protein useful for vaccination against rotavirus |
US20240050555A1 (en) | 2022-04-05 | 2024-02-15 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1061898A (en) | 1963-03-07 | 1967-03-15 | Philips Electronic Pharma | Method for protecting dogs against canine distemper |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) * | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
AU570940B2 (en) * | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
EP0162738A1 (en) | 1984-04-09 | 1985-11-27 | MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP | Production of pseudorabies virus subunit vaccines |
US5242829A (en) * | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
EP0261940A3 (en) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Pseudorabies vaccines and dna vectors for recombination with pox viruses |
AU605567B2 (en) * | 1987-03-11 | 1991-01-17 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
EP0297924A3 (en) * | 1987-07-01 | 1990-07-11 | City Of Hope | Recombinant vaccinia virus expressing hsv 1 gb |
DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
WO1990001546A1 (en) * | 1988-08-05 | 1990-02-22 | Applied Biotechnology, Inc. | Equine herpesvirus-1 vaccine |
IE71643B1 (en) | 1990-11-20 | 1997-02-26 | Virogenetics Corp | A recombinant poxviral vaccine for canine distemper |
-
1990
- 1990-04-04 US US07/502,834 patent/US5338683A/en not_active Expired - Lifetime
- 1990-04-12 CA CA002014465A patent/CA2014465C/en not_active Expired - Lifetime
- 1990-04-16 AT AT0902590A patent/AT405184B/de active
- 1990-04-16 AU AU55520/90A patent/AU625623B2/en not_active Expired
- 1990-04-16 KR KR1019900702630A patent/KR920700289A/ko not_active Application Discontinuation
- 1990-04-16 DE DE4090565A patent/DE4090565C2/de not_active Expired - Lifetime
- 1990-04-16 WO PCT/US1990/002094 patent/WO1990012882A1/en active Application Filing
- 1990-04-16 NL NL9020677A patent/NL195016C/nl not_active IP Right Cessation
- 1990-04-16 CH CH3982/90A patent/CH682671A5/fr not_active IP Right Cessation
- 1990-04-16 DE DE19904090565 patent/DE4090565T/de active Pending
- 1990-04-16 JP JP02507078A patent/JP3083839B2/ja not_active Expired - Lifetime
- 1990-04-17 IT IT20063A patent/IT1241119B/it active IP Right Grant
- 1990-04-17 FR FR9004910A patent/FR2647808B1/fr not_active Expired - Lifetime
- 1990-04-17 BE BE9000425A patent/BE1004369A5/fr not_active IP Right Cessation
- 1990-04-18 IE IE138090A patent/IE61098B1/en not_active IP Right Cessation
-
1991
- 1991-09-27 GB GB9120655A patent/GB2246784B/en not_active Expired - Lifetime
- 1991-10-15 DK DK199101743A patent/DK176464B1/da not_active IP Right Cessation
- 1991-10-16 LU LU88018A patent/LU88018A1/fr unknown
-
1993
- 1993-09-21 US US08/124,668 patent/US5482713A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/476,500 patent/US6183750B1/en not_active Expired - Lifetime
-
1999
- 1999-12-28 JP JP37276499A patent/JP3246735B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AT405184B (de) | 1999-06-25 |
JP2000157292A (ja) | 2000-06-13 |
DE4090565C2 (de) | 2000-03-09 |
DK174391D0 (da) | 1991-10-15 |
AU625623B2 (en) | 1992-07-16 |
JPH04505248A (ja) | 1992-09-17 |
NL9020677A (nl) | 1992-02-03 |
IT9020063A0 (it) | 1990-04-17 |
GB2246784B (en) | 1993-04-28 |
DE4090565T (it) | 1992-05-14 |
CH682671A5 (fr) | 1993-10-29 |
LU88018A1 (fr) | 1992-03-11 |
WO1990012882A1 (en) | 1990-11-01 |
IT1241119B (it) | 1993-12-29 |
US5482713A (en) | 1996-01-09 |
GB9120655D0 (en) | 1991-11-27 |
US5338683A (en) | 1994-08-16 |
DK174391A (da) | 1991-12-12 |
JP3083839B2 (ja) | 2000-09-04 |
IT9020063A1 (it) | 1991-10-17 |
AU5552090A (en) | 1990-11-16 |
CA2014465C (en) | 1999-06-15 |
KR920700289A (ko) | 1992-02-19 |
IE901380L (en) | 1990-10-17 |
BE1004369A5 (fr) | 1992-11-10 |
FR2647808B1 (fr) | 1995-03-03 |
JP3246735B2 (ja) | 2002-01-15 |
NL195016C (nl) | 2003-06-10 |
CA2014465A1 (en) | 1990-10-17 |
GB2246784A (en) | 1992-02-12 |
ATA902590A (de) | 1998-10-15 |
IE61098B1 (en) | 1994-09-21 |
US6183750B1 (en) | 2001-02-06 |
FR2647808A1 (fr) | 1990-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK176464B1 (da) | Rekombinant poxvirus og vaccine mod herpesvirus indeholdende dette | |
LU88000A1 (fr) | Systeme de selection d'hotes de poxvirus du recombinaision | |
US5766599A (en) | Trova fowl pox virus recombinants comprising heterologous inserts | |
US5688920A (en) | Nucleotide and amino acid sequences for canine herpesvirus GB, GC and GD and uses therefor | |
Guo et al. | Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity | |
US6605465B1 (en) | Methods for avoiding maternal immunity | |
US6017542A (en) | Nucleotide and amino acid sequences of canine herpesvirus GD and uses therefor | |
NL195085C (nl) | Herpesvirus recombinant pokkenvirus. | |
CA2259047C (en) | Innoculation kits for avoiding maternal immunity | |
AU701599B2 (en) | TROVAC fowlpox virus recombinants comprising heterologous inserts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUP | Patent expired |